

July 21, 1970

Dr. William R. Martin
Chief, NIMH Addiction Research Center
P. O. Box 2000
Lexington, Kentucky 40501

Dear Bill,

The need for a sustained release form of antagonist is clear. Your letter of July 13 describes some steps which may be necessary to test the feasibility of Dr. Yolles' preparation.

Al Freedman is in Europe and I am leaving on August 4. He and I will both be together again in New York after September 3 and I would suggest that we arrange to meet - with Dr. Yolles and any other interested participants - during the second or third week in September. This can best be arranged on our return.

Incidentally, you are aware that Endo Laboratories on July 8 announced a decision to discontinue supplies of naloxone for clinical trials. In response to inquiries from friends on the *New York Times* and CBS-TV, DuPont reversed their decision and our clinical programs, despite the improbability of its success, will continue. A copy of Mr. Serchuck's letter is enclosed for your interest.

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kt

enc.